Genetic engineering in the United States

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

Monopoly, Patent, Genetic engineering in the United States, War on Cancer, Articles, Life sciences

This latest patent is the twenty first patent granted to AnPac Bio in the United States.

Key Points: 
  • This latest patent is the twenty first patent granted to AnPac Bio in the United States.
  • We are pleased that AnPac Bio has been granted our first disease treatment patent, whose disease treatment related claims will be licensed to our new cancer treatment joint venture (while future disease treatment only patent applications will be transferred to the cancer treatment joint venture).
  • We are also pleased that our cancer treatment joint venture has secured funding to speed up its cancer treatment developments.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection as well as cancer treatment, with 142 issued patents as of March 31, 2021.

Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competition

Retrieved on: 
Monday, November 16, 2020
Technology, Engineering, Genetics, Nanotechnology, Manufacturing, Biotechnology, Health, University, Education, Synthetic biology, Massachusetts Institute of Technology, Life sciences, Biology, Biotechnology, Genetic engineering in the United States, International Genetically Engineered Machine, Registry of Standard Biological Parts, IGEM, Twist Bioscience, Ginkgo Bioworks, Science and technology

As a long-time supporter of iGEM, in 2019 Twist provided a streamlined approach to change the way iGEM Competition teams contribute to the Registry of Standard Biological Parts, a free online database for synthetic biologists.

Key Points: 
  • As a long-time supporter of iGEM, in 2019 Twist provided a streamlined approach to change the way iGEM Competition teams contribute to the Registry of Standard Biological Parts, a free online database for synthetic biologists.
  • In addition to synthesizing the parts, Twist is providing all iGEM teams with 10kB of synthetic DNA to support their project.
  • A new addition to the iGEM line up this year, Twist is partnering with its customer Ginkgo Bioworks on the Ginkgo Challenge during the iGEM workshop sessions.
  • The next generation of synthetic biologists across the globe compete at iGEM, bringing their best ideas for solving global challenges head-on, said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States

Intellectual property law, Monopoly, Patent, Genetic engineering in the United States, Patent law, Outline of patents

The new patent covers novel medical device structures, methods, and biophysical related test parameters for improved detection performance.

Key Points: 
  • The new patent covers novel medical device structures, methods, and biophysical related test parameters for improved detection performance.
  • The newly granted patent this week brings the total number of issued and granted AnPac Bio patents to nineteen in the United States.
  • AnPac Bio has always focused on technological innovation and building a strong patent and IP portfolio in the space of cancer screening and detection.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 granted patents as of December 31, 2019.

Twist Bioscience and iGEM Partner to Provide Synthetic DNA for iGEM Competition and Registry

Retrieved on: 
Monday, April 15, 2019
Research, Science, Articles, Branches of biology, Biology, Synthetic biology, Massachusetts Institute of Technology, Biotechnology, Genetic engineering in the United States, International Genetically Engineered Machine, Twist Bioscience, IGEM, DNA synthesis

Now, through this collaboration between Twist and iGEM, competition teams no longer have to factor in the time, effort and resources needed to generate and ship their part samples to the Registry.

Key Points: 
  • Now, through this collaboration between Twist and iGEM, competition teams no longer have to factor in the time, effort and resources needed to generate and ship their part samples to the Registry.
  • Instead, by the end of the competition, teams will now submit their part sequences and documentation to the Registry.
  • The iGEM Competition is the preeminent synthetic biology event of the year, engaging more than 40,000 students worldwide, said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

International Student Teams, Industry Leaders, Executives and Investors Descend Upon Boston for the iGEM Giant Jamboree, Synthetic Biology's Largest Innovation Event

Retrieved on: 
Tuesday, October 23, 2018
Biology, Synthetic biology, Massachusetts Institute of Technology, Genetic engineering in the United States, International Genetically Engineered Machine, Nature, Technology, Biotechnology, IGEM, Jamboree

What: iGEM , the pioneering organization of the synthetic biology industry, will host its 15th annual Jamboree on October 24 - 28, 2018.

Key Points: 
  • What: iGEM , the pioneering organization of the synthetic biology industry, will host its 15th annual Jamboree on October 24 - 28, 2018.
  • The Jamboree is the synthetic biology industry's largest innovation event and the culmination of the iGEM competition.
  • Ferment will offer investors, executives and influencers a sneak peek at the people and ideas driving the future of the synthetic biology industry.
  • Who: 3,200+ attendees including student competitors (ranging from high school to graduate), as well as professors, industry leaders, executives and investors